Tirzepatide (trade name Mounjaro) helps perform several critical bodily functions. It is a compound that mimics hormones called ‘glucagon-like peptide1’ or ‘GLP-1’. This drug may help decrease food intake while also keeping metabolism steady. Studies on Tirezepatide for weight loss have shown that nearly 75% of clinical trial participants lost at least 15% of their body weight in 16 weeks. The drug is a GIP and GLP-1 receptor agonist. Agonists are drugs that activate receptors. In this case, GIP and GLP-1 regulate gut hormones called incretins, which help our bodies know when we feel full. It is an FDA-approved product for patients with Type 2 Diabetes, & off-label use for chronic obesity leading towards metabolic diseases.
Benefits of Tirzepatide:
Improved glycemic control: Tirzepatide helps regulate blood sugar levels, which is particularly beneficial for individuals with type 2 diabetes.
Weight loss: Early research suggested that Tirzepatide might aid in weight loss. This is because GLP-1 receptor agonists like Tirzepatide can help control appetite and promote feelings of fullness, which can lead to reduced calorie intake.
Reduced risk of cardiovascular disease: By helping to control blood sugar levels and promote weight loss, Tirzepatide might potentially decrease the risk of cardiovascular disease, which is a major concern for individuals with type 2 diabetes.
Once-weekly administration: Tirzepatide is a long-acting medication that only needs to be administered once a week, which could improve patient compliance compared to medications that need to be taken more frequently.
Administration: Sub Q injection, once weekly, recommended 16-week program